Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Together with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
Dutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.